Table 3 The expression of ANGPTL4 in ovarian cancer based on TCGA database
characteristics | Low expression of ANGPTL4 | High expression of ANGPTL4 | p value |
|---|---|---|---|
n | 190 | 191 | Â |
Clinical stage, n (%) | Â | Â | 0.4442 |
 Stage I and Stage II | 9 (2.4%) | 15 (4%) |  |
 Stage III | 150 (39.7%) | 146 (38.6%) |  |
 Stage IV | 30 (7.9%) | 28 (7.4%) |  |
Tumor status, n (%) | Â | Â | 0.2177 |
 Tumor free | 40 (11.8%) | 32 (9.5%) |  |
 With tumor | 126 (37.3%) | 140 (41.4%) |  |
Histologic grade, n (%) | Â | Â | 0.5159 |
 G1&G2 | 25 (6.7%) | 21 (5.7%) |  |
 G4&G3 | 160 (43.1%) | 165 (44.5%) |  |
Venous invasion, n (%) | Â | Â | 0.5253 |
 No | 25 (23.8%) | 16 (15.2%) |  |
 Yes | 35 (33.3%) | 29 (27.6%) |  |
Lymphatic invasion, n (%) | Â | Â | 0.9361 |
 No | 26 (17.4%) | 22 (14.8%) |  |
 Yes | 54 (36.2%) | 47 (31.5%) |  |
ESM1, n (%) | Â | Â | 0.0018 |
 Low | 110 (28.9%) | 80 (21%) |  |
 High | 80 (21%) | 111 (29.1%) |  |
VEGFA, n (%) | Â | Â | 2.29E-07 |
 Low | 120 (31.5%) | 70 (18.4%) |  |
 High | 70 (18.4%) | 121 (31.8%) |  |